Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

Blood (2024) 144 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2024-200501

Published: 2024

Journal Articles

Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Arnon Nagler, Allain-Thibeault Ferhat, Didier Blaise, Yener Koc, Emanuele Angelucci, Alessandro Busca, Jiri Pavlu, Stefania Bramanti, Maija Itäla-remes, Maria Aranzazu Bermudez Rodriguez, Jan Vydra, Alexander Kulagin, Ali Bazarbachi, Bipin N. Savani, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2024-193936

Published: 2024

Journal Articles

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Laura G.M. Daenen, Lotte Van Der Wagen, Edouard F. Bonneville, Lucia Lopez Corral, Laimonas Griskevicius, Martin Bornhäuser, Yves Beguin, Maija Itala-Remes, Jorinde D. Hoogenboom, Liesbeth C. de Wreede, Florent Malard, Christian Chabannon, Francesco Dazzi, Annalisa Ruggeri, Jurgen Kuball

Blood (2024) 144 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2024-201358

Published: 2024

Journal Articles

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2024-203487

Published: 2024

Journal Articles

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2024-204672

Published: 2024

Journal Articles

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Blood blood.2024024968.

https://doi.org/10.1182/blood.2024024968

Published: 2024

Includes: Supplemental data

Journal Articles

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Blood (2024) 143 (24): 2534–2543.

https://doi.org/10.1182/blood.2023023697

Published: 2024

Includes: Supplemental data

Journal Articles

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2023-174368

Published: 2023

Journal Articles

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2023-180075

Published: 2023

Journal Articles

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2023-185685

Published: 2023

Journal Articles

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 657.

https://doi.org/10.1182/blood-2023-182823

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelodysplastic Neoplasms Allografted with an Unrelated Donor: A Registry Study of the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 898.

https://doi.org/10.1182/blood-2023-178287

Published: 2023

Journal Articles

Somatic Mutations in T Cells in Patients with Hematological Diseases

Sofie Lundgren, Timo Järvinen, Mikko A Keränen, Jason Theodoropoulos, Daehong Kim, Urpu Salmenniemi, Gunilla Walldin, Paula Savola, Tiina Kelkka, Hanna Rajala, Pekka Ellonen, Eva Hellström-Lindberg, Maija Itälä-Remes, Mikko Myllymäki, Matti Kankainen, Satu Mustjoki

Blood (2022) 140 (Supplement 1): 5496–5497.

https://doi.org/10.1182/blood-2022-163112

Published: 2022

Journal Articles

Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Blood (2022) 140 (Supplement 1): 7585–7586.

https://doi.org/10.1182/blood-2022-156076

Published: 2022

Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Blood (2022) 140 (Supplement 1): 2020–2022.

https://doi.org/10.1182/blood-2022-159391

Published: 2022

Journal Articles

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Jacques-Emmanuel Galimard, Myriam Labopin, Iman Abou Dalle, Bruno Lioure, Johan A. Maertens, Maija Itälä-Remes, Maria Pilar Gallego Hernanz, Gesine Bug, Josep-Maria Ribera, Alain Gadisseur, Christoph Schmid, Xavier Poiré, Manuel Jurado Chacón, Frederic Baron, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 735–736.

https://doi.org/10.1182/blood-2022-162162

Published: 2022

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Blood (2021) 138 (Supplement 1): 485.

https://doi.org/10.1182/blood-2021-152391

Published: 2021

Journal Articles

Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141757

Published: 2020

Journal Articles

Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2019) 134 (Supplement_1): 3281.

https://doi.org/10.1182/blood-2019-125369

Published: 2019

Journal Articles

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation

Giorgia Battipaglia, Myriam Labopin, Nicolaus Kröger, Antonin Vitek, Boris Afanasyev, Inken Hilgendorf, Johannes Schetelig, Arnold Ganser, Didier Blaise, Maija Itälä-Remes, Jakob R. Passweg, Francesca Bonifazi, Jurgen Finke, Annalisa Ruggeri, Arnon Nagler, Mohamad Mohty

Blood (2019) 134 (11): 892–899.

https://doi.org/10.1182/blood.2019000487

Published: 2019

Includes: Supplemental data

NARROW

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelodysplastic Neoplasms Allografted with an Unrelated Donor: A Registry Study of the Chronic Malignancies Working Party of the EBMT

Somatic Mutations in T Cells in Patients with Hematological Diseases

Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT

Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only